Notable Labs picked up $10 million in series A financing to advance its drug-testing service that helps oncologists identify the most appropriate combination of drugs for individuals with blood cancers.

CEO Matthew De Silva co-founded Notable said, “We wanted to try to fight, but didn’t have any treatment options available to us that were compelling. Notable’s service involves collecting a blood sample or bone marrow aspirate from a patient and testing individual drugs and combinations on the patient’s cancer cells, as well as their healthy white blood cells.”

 “Notable’s purpose is to change the way cancer is treated. Our whole team lives and breathes this mission of developing cancer solutions that are personalized, and that can make an immediate positive impact on patients’ lives … We’re working closely with forward-thinking oncologists and researchers at top U.S. and Canadian cancer centers to make personalized combination treatment a reality,” he said in a statement.

The company comes up with a report of the results, which an oncologist will use to guide treatment decisions for the patient.

The company is taking a functional rather than genomic approach to personalized therapy—instead of sequencing the genome of a tumor, Notable tests combinations directly on the patient’s cancer cells to find the best treatment.